LUNA INNOVATIONS INCORPORATED — Department of Health and Human Services SBIR Phase I: ODCDC

Description

PoliomyelitisPoliois a highly infectious disease that primarily affects young childrenCurrentlythe live attenuated oral poliomyelitis vaccineOPVis the vaccine used to prevent polio outbreaks and stop transmission of wild poliovirusesHoweversometimes OPV has the ability to revert to a form that can cause paralysis or poliomyelitiswhich will inevitably lead to new polio outbreaksIn most developed countriesinactivated polio vaccineIPVis already the preferred way to eliminate the risk of vaccine associated paralysisThereforethe new strategy for polio eradication includes the introduction of an inactivated polio vaccineIPVinto all routine immunization programs followed by a phased withdrawal of OPVThe availability of IPV in developing countries is limited because IPV is more expensive than OPVprimarily due to storage costsIn order to produce an inexpensive thermally stable Sabin IPVLuna will utilize its demonstrated stabilization sol gelwhich will form an encapsulating preservation matrix for ambient transport and storageC andRHof Sabin IPVDuring Phase ILuna will work with Intravaccthe Institute for Translational Vaccinologythe leading developer of Sabin IPV technologyin order to demonstrate Luna s sol gel to provide a thermo stable storage technology for Sabin IPVPr ovide key wordsmaximumto identify the research or technologyPolioSabinIPVthermostable Provide a thermo stable storage technology for Sabin IPV